Paras Bio­phar­ma­ceu­ti­cals Fin­land Oy Wel­comes Michael Sol­dan as a Senior Advi­sor

Paras Bio­phar­ma­ceu­ti­cals Fin­land Oy (Paras Bio­phar­ma) has announced that Michael Sol­dan has been appoint­ed as a Senior Advi­sor to the com­pa­ny and a key mem­ber of the Paras Bio­phar­ma team.

“The addi­tion of Michael to Paras Biopharma’s team will be instru­men­tal in set­ting up the com­pa­ny for con­tin­ued growth and suc­cess,” said Ashesh Kumar (CEO). “Michael is a high­ly respect­ed leader in the biotech strate­gic con­sult­ing indus­try, with more than 15 years of expe­ri­ence in cor­po­rate and com­mer­cial strat­e­gy, mar­ket access, port­fo­lio man­age­ment, and busi­ness devel­op­ment & licens­ing,” he added.

“With Michael’s exper­tise, we will fur­ther accel­er­ate Paras Biopharma’s Romi­plostim Biosim­i­lar pro­gram, mov­ing it toward suc­cess­ful com­mer­cial­iza­tion,” stat­ed Dr Mark Jack­son – Admin­is­tra­tion Lead.

“I am very excit­ed to be team­ing up with Paras Bio­phar­ma and its team to dri­ve the company’s Romi­plostim Biosim­i­lar pro­gram for­ward. I look for­ward to pro­vid­ing valu­able guid­ance and strate­gic insight to sup­port its com­mer­cial­iza­tion,” said Dr. Michael Sol­dan.

About Michael Sol­dan

Dr. Michael Sol­dan is a senior leader in the biosim­i­lars and bio­log­ics indus­try, with a focus on immunol­o­gy, oncol­o­gy, and orphan drugs. Before start­ing his con­sult­ing firm (MSBiotech­Con­sult­ing) in 2024, Michael led and tran­si­tioned the biosim­i­lar busi­ness of Mer­ck Serono, guid­ing its strate­gic move to Fre­se­nius Kabi, where he suc­cess­ful­ly over­saw the devel­op­ment and launch of mul­ti­ple biosim­i­lars. He lat­er joined Pol­phar­ma Bio­log­ics Group, where he served as CEO and played a key role in the com­pa­ny’s expan­sion and the approval of key biosim­i­lar prod­ucts. Through­out his career, Michael has built a strong under­stand­ing of the com­plex­i­ties of biosim­i­lar devel­op­ment, includ­ing clin­i­cal advance­ment, reg­u­la­to­ry path­ways, and com­mer­cial­iza­tion strate­gies. His exten­sive exper­tise spans mul­ti­ple ther­a­peu­tic areas, includ­ing immunol­o­gy, oncol­o­gy, and orphan drugs.

About Paras Bio­phar­ma­ceu­ti­cals

Paras Bio­phar­ma is a Finnish bio­phar­ma­ceu­ti­cal tech­nol­o­gy devel­op­ment com­pa­ny spe­cial­iz­ing in bio­log­ics and biosim­i­lar tech­nolo­gies. Since its incep­tion in 2012, the com­pa­ny has devel­oped a port­fo­lio of biosim­i­lars and bio­log­ics tar­get­ing dis­eases such as osteo­poro­sis, rheuma­toid arthri­tis, and meta­bol­ic dis­or­ders.

In addi­tion, Paras Bio­phar­ma has devel­oped a pro­pri­etary tech­nol­o­gy plat­form, which includes:

• Dia­brid^®, Bio­mul­ti­fold^®, Noble­cleav^®, and Cyto­fold Struc­tQuant^®, designed to enhance the high-pro­duc­tiv­i­ty pro­duc­tion and high-qual­i­ty expres­sion of pep­tides and pro­teins.

Paras Bio­phar­ma also offers Bio­log­ics CDMO Ser­vices, lever­ag­ing its state-of-the-art bio­log­ics pro­duc­tion facil­i­ty in Fin­land. The 25,000 ft² pro­duc­tion plant includes a clas­si­fied 4,300 ft² clean­room, pro­vid­ing capa­bil­i­ties for fer­men­ta­tion, extrac­tion, purifi­ca­tion, fil­tra­tion, and freeze-dry­ing for micro­bial-based bio­phar­ma­ceu­ti­cals.

Con­tact Infor­ma­tion

Dr Mark Jack­son

Admin­is­tra­tion Lead, Paras Bio­phar­ma­ceu­ti­cals Fin­land

mark.jackson@parasbiopharma.com

Source: Paras Bio­phar­ma­ceu­ti­cals Fin­land Oy